NCT00882362

Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 155 (actual)
• Sponsor: Otsuka Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor (SNRI), in subjects with major depressive disorder.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	OPC-14597 (Aripiprazole)	administered orally once daily, 3 to 15 mg daily, 52 weeks

Timeline

• Start date: 2009-03-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2009-04-16
• Last updated: 2014-02-10
• Results posted: 2014-02-10

Locations

8 sites across 1 country: Japan